Name | NV-5138 |
---|
Description | NV-5138, a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2. NV-5138 possesses rapid antidepressant effects[1][2]. |
---|---|
Related Catalog | |
Target |
mTORC1[1]. |
In Vivo | NV-5138 is found to be essentially 100% orally bioavailable with an elimination half-life in plasma of ~ 3 h determined following intravenous and oral dosing in rats[1]. NV-5138 (160 mg/kg, po, single dose) rapidly increases levels of phospho-mTOR as well as the downstream targets, phospho-p70S6K1, and phosphor-4EB-P1, in synaptosomal preparations of PFC[2]. NV-5138 (80 mg/kg, po, daily for a total of 7 days) also produces antidepressant effects[2]. Animal Model: Male Sprague-Dawley rats weighing 250-260 g[2]. Dosage: 40, 80, 160 mg/kg. Administration: PO, single dose (160 mg/kg) or daily for a total of 7 days (40, 80 mg/kg). Result: Produces antidepressant effects. Animal Model: Male Sprague–Dawley (SD) rats weighed 250-400 g[1]. Dosage: 1 mg/kg, 5 mg/kg (Pharmacokinetic Design). Administration: I.V at 1 mg/kg and PO at 5 mg/kg. Result: Essentially 100% orally bioavailable with an elimination half-life in plasma of ~ 3 h. |
References |
Molecular Formula | C7H13F2NO2 |
---|---|
Molecular Weight | 181.18 |
Storage condition | -20°C |